After SARS2 challenge, the GSHs experienced clinical signs consistent with virus infection regardless of prior-FLUAV exposure starting at 2 dpc (SARS2: range 1.15–6.5% and FLUAV-SARS2: range 1.19–7.4%) and continued to deteriorate until 6 dpc when the study was terminated (SARS2: range 7.7–10.2% and FLUAV-SARS2: range 4.3–11.7%) (Fig 1B). Here, SARS2 is linked to viral infectious disease.